A novel human intestinal organoid platform with peristaltic function for drug discovery and pre-clinical testing in GI motility disorders
Active Project Grant Awarded Last action
- Award ID
- R43TR006331
- Recipient
-
Intero Biosystems Inc. UEI CTNPP6BWF453
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $349,824
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date 34% complete
- Place of performance
- Ann Arbor, MI 48108, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health National Center for Advancing Translational Sciences awarded Intero Biosystems Inc. $349,824 on July 15, 2026, for a Phase I Small Business Innovation Research project to develop a human peristaltic intestinal organoid platform for drug discovery and preclinical testing in gastrointestinal motility disorders.
The recipient will engineer and validate a scalable human peristaltic intestinal organoid (peristaltic-HIO) platform that integrates organ-level quantitative peristalsis measurements with high-content imaging and single-nucleus transcriptomics. The platform will deliver multimodal functional fingerprints to reveal drug mechanisms and support predictive modeling for therapeutic efficacy and gastrointestinal-specific toxicity. Aim 1 focuses on engineering peristaltic-HIOs for 96-well scalability, reproducibility, and cellular fidelity using design-of-experiments optimization and single-cell and spatial quality control signatures. Aim 2 establishes a quantitative, screen-ready peristalsis assay and benchmarks pharmacologic responsiveness to canonical neuromuscular modulators to define assay dynamic range and acceptance criteria. The project will deliver a validated human peristalsis model with locked manufacturing and quality control protocols, a reference pharmacology panel, and a screen-ready assay upon completion.
Work is performed in Ann Arbor, Michigan. The period of performance runs from July 15, 2026, through July 14, 2027. The award is issued under CFDA 93.350, National Center for Advancing Translational Sciences.
Description
- Abstract
- Gastrointestinal (GI) motility disorders such as irritable bowel syndrome and inflammatory bowel disease impose substantial medical and economic burdens, yet drug development remains hampered by preclinical models that fail to recapitulate human physiology and pathophysiology. Our long-term goal is to enable mechanism-informed discovery of safe and effective therapeutics by developing novel human models that accurately reflect human biology. The overall objective of this phase I sbir is to establish, validate, and deploy a scalable human PERISTALTIC intestinal organoid (PERISTALTIC-HIO) platform that couples quantitative functional readouts with deep molecular and cellular profiling. Our strong preliminary data shows self-organized PERISTALTIC activity in pluripotent stem cell-derived hios containing the enteric nerons, smooth muscle, interstitial cells of cajal, epithelium, and endothelium, and on our automated live-imaging pipeline for contraction frequency, amplitude, and coordination. We will integrate organ-level quantitative peristalsis measurements with high- content imaging and single-nucleus transcriptomics, yielding multimodal "fingerprints" that both reveal drug mechanisms and that will power predictive models for efficacy and GI-specific toxicity. We will pursue two aims: aim 1-engineer and rigorously validate PERISTALTIC-hios for 96-well scalability, reproducibility, and cellular fidelity using design-of-experiments optimization and single-cell/spatial QC signatures. Aim 2-establish a quantitative, screen-ready peristalsis assay and benchmark pharmacologic responsiveness to canonical neuromuscular modulators to define assay dynamic range and acceptance criteria. At the end of phase I, we will have a validated human peristalsis model with locked manufacturing and QC, a reference pharmacology panel and assay performance metrics suitable for discovery, and an integrated "HIO atlas" and predictive models that accelerate HIT identification, repurposing, and lead optimization.
Quick answers
Who received award R43TR006331?
R43TR006331 was awarded to Intero Biosystems Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on July 15, 2026.
How much is award R43TR006331 worth?
$349,824 has been obligated on R43TR006331.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award